(Q42982310)

12 November 2017

title

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial (English)

1 reference

12 November 2017

1 reference

ChEBI release 2020-05-28

10

Stefan Zeuzem

1 reference

12 November 2017

Sandra De Meyer

1

1 reference

12 November 2017

Inge Dierynck

2

1 reference

12 November 2017

Anne Ghys

3

1 reference

12 November 2017

Maria Beumont

4

1 reference

12 November 2017

Bjorn Daems

5

1 reference

12 November 2017

Ben Van Baelen

6

1 reference

12 November 2017

James C Sullivan

7

1 reference

12 November 2017

Douglas J Bartels

8

1 reference

12 November 2017

Tara L Kieffer

9

1 reference

12 November 2017

Gaston Picchio

11

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

12 November 2017

1 reference

12 November 2017

volume

56

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

2106-2115

1 reference

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

12 November 2017

cites work

1 reference

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Hepatitis C virus genetic variability: pathogenic and clinical implications

21 January 2018

1 reference

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials

21 January 2018

1 reference

The Los Alamos hepatitis C sequence database

21 January 2018

1 reference

Simplified exact analysis of case-referent studies: matched pairs; dichotomous exposure

21 January 2018

1 reference

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.25962

1 reference

12 November 2017

1 reference